RE:RE:RE:from the AGMBut when reading this:
Under long term and accelerated stability storage conditions, the drug is evaluated by High Performance Liquid Chromatography (“HPLC”) to separate, identify and quantify each chemical component to a very high degree of resolution to assess if any change occurs in the chemical composition over time.
TLD-1433 has demonstrated that it has remained stable at these reported time periods and according to Health Canada guidelines, accelerated and long-term stability has now been proven at 6 months and 36 months, respectively, allowing use in treating patients in a clinical study.
maybe the next indication will not be GBM, considering that Rutherrin has not been tested for long-term stability yet, and certainly not for 36 months. Unless because Rutherrin is a mix of 2 already stable ingredients (TLD-1433 and transferrin), they would not have to confirm such stability (which I highly doubt) ...
So maybe our next indication will be one using TLD-1433 only, that is one that doesn't require Rutherrin. So that could the cervical one, for example. This one doesn't seem to require special equipment other than pretty much standard tools already used by specialist of that indication. Could they even use our current DFOC or a more simplifier version of it, like a linear fiber, when looking at this image, in order to go deliver the light, after having instilled the cavity when the patient is in an angled position:
